Dubai Investments Innovates with Globalpharma Partnership

Dubai Investments PJSC, a prominent multi-asset investment group based in the United Arab Emirates, is making waves in the pharmaceutical industry through its wholly-owned subsidiary, Globalpharma. The latest development sees Globalpharma collaborating with India's ZIM Laboratories to introduce EU-certified Oral Dispersible Film (ODF) technology to the UAE. This strategic partnership was announced at the AIM Congress 2025, underscoring the UAE's growing influence in global pharmaceutical innovation.

The ODF technology represents a significant advancement in drug delivery methods, offering thin, fast-dissolving strips that melt in the mouth without water. This innovation is particularly beneficial for children, elderly patients, and those with swallowing difficulties, enhancing patient compliance and treatment efficacy. ZIM Labs' proprietary technology seamlessly incorporates medications into these stable, rapid-acting films, setting a new benchmark in the region's pharmaceutical capabilities.

Globalpharma's General Manager, Dr. Basem Al-Barahmeh, emphasized the importance of this development, stating that by localizing ODF production within the UAE, Globalpharma is not only introducing innovative treatments but also setting a benchmark for pharmaceutical manufacturing in the region. With a dedicated production line and a growing portfolio of ten ODF products, Globalpharma is poised to lead the way in advanced drug manufacturing.

This partnership aligns with Globalpharma's vision to invest in innovations that elevate regional healthcare standards and position the UAE as a leader in advanced drug manufacturing. The collaboration was witnessed by notable figures, including H.E. Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade and Chairman of the Board of Emirates Drug Establishment, further highlighting the significance of this venture.

From an investment perspective, Dubai Investments PJSC's strategic move to enhance its pharmaceutical portfolio through Globalpharma indicates a forward-thinking approach to business diversification and growth. The introduction of EU-certified ODF technology is likely to strengthen the company's position in the healthcare sector, potentially driving sustainable financial returns for shareholders.

Given the promising outlook of this partnership and the growing demand for innovative healthcare solutions, investors might consider holding their positions in Dubai Investments PJSC. The company's commitment to expanding its pharmaceutical capabilities and its strategic collaborations suggest a stable and potentially rewarding future.